ArticleObstetrics and gynecology2019
Medication-Assisted Treatment Use Among Pregnant Women With Opioid Use Disorder.
Article in Obstetrics and gynecology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Evidence-based framework for identifying opioid use disorder in administrative data: A systematic review and methodological development study.Pain medicine (Malden, Mass.) · 2026Pooled it
- Interventions for opioid use disorder during pregnancy: a scoping review.Frontiers in psychiatry · 2026Pooled it
- Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.JAMA pediatrics · 2022Pooled it
- Racial and Ethnic Inequities in the Receipt of Medications to Treat Opioid Use Disorder Among Pregnant People: A Meta-analysis.Journal of addiction medicinePooled it
- Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study.Journal of substance use and addiction treatment · 2023Trial
- Effects of prenatal methadone and buprenorphine exposure on motivated responding for sucrose and gene expression in adult male and female rats.Addiction neuroscience · 2026Article
- Opioid use disorder and medication for opioid use disorder among pregnant women with commercial insurance in the United States, 2016-2020.Drug and alcohol dependence · 2026Article
- Tailored strategies to reduce opioid overdose deaths for pregnant and postpartum women: Examples and lessons learned from the HEALing Communities Study.Journal of substance use and addiction treatment · 2025Article
- Buprenorphine and norbuprenorphine concentrations associated with clinical withdrawal during pregnancy.Drug and alcohol dependence · 2025Article
- Association between buprenorphine dose and outcomes among pregnant persons with opioid use disorder.American journal of obstetrics and gynecology · 2025Article
- Systemic barriers and stigma: Healthcare provider perspectives on perinatal and neonatal care in the fentanyl crisis.Journal of substance use and addiction treatment · 2025Article
- Medication for Opioid Use Disorder and Treatment Retention Among Pregnant Individuals.JAMA network open · 2025Article
- Feasibility trial of a technology-delivered intervention for opioid use disorder recovery postpartum.Journal of child & adolescent substance abuse · 2025Article
- Spatial Patterns of Delivery Hospitalizations with Opioid Use Disorder in Pennsylvania.Substance use & misuse · 2025Article
- Knowledge, experiences, and perceptions of medications for opioid use disorder among Black Kentuckians.Annals of medicine · 2024Article
- Services for perinatal patients with opioid use disorder: a comprehensive Baltimore City-wide 2023 assessment.Addiction science & clinical practice · 2024Article
- Development of an Educational Brochure about Treatment Options for Pregnant Women with Opioid Use Disorders.Pharmacy (Basel, Switzerland) · 2024Article
- "Instead of just taking my baby, they could've actually given me a chance": Experiences with plans of safe care among birth parents impacted by perinatal substance use.Child abuse & neglect · 2024Article
- Implementation and early effects of medicaid policy interventions to promote racial equity in pregnancy and early childhood outcomes in Pennsylvania: protocol for a mixed methods study.BMC health services research · 2024Article
- Trends and Disparities in Perinatal Opioid Use Disorder Treatment in Medicaid, 2007-2012.Medical care research and review : MCRR · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
objectiveTo evaluate temporal trends in medication-assisted treatment use among pregnant women with opioid use disorder.
methodsWe conducted a retrospective cohort study using Pennsylvania Medicaid administrative data. Trends in medication-assisted treatment use, opioid pharmacotherapy (methadone and buprenorphine) and behavioral health counselling, were calculated using pharmacy records and procedure codes. Cochrane-Armitage tests evaluated linear trends in characteristics of pregnant women using methadone compared with buprenorphine.
resultsIn total, we evaluated 12,587 pregnancies among 10,741 women with opioid use disorder who had a live birth between 2009 and 2015. Across all years, 44.1% of pregnant women received no opioid pharmacotherapy, 27.1% used buprenorphine, and 28.8% methadone. Fewer than half of women had any behavioral health counseling during pregnancy. The adjusted prevalence of methadone use declined from 31.6% (95% CI 29.3-33.9%) in 2009 to 25.2% (95% CI 23.3-27.1%) in 2015, whereas the adjusted prevalence of buprenorphine use increased from 15.8% (95% CI 13.9-17.8%) to 30.9% (95% CI 28.8-33.0%). Greater increases in buprenorphine use were found in geographic regions with large metropolitan centers, such as the Southwest (plus 24.9%) and the Southeast (plus 12.0%), compared with largely rural regions, such as the New West (plus 5.2%). In 2015, the adjusted number of behavioral health counseling visits during pregnancy was 3.4 (95% CI 2.6-4.1) among women using buprenorphine, 4.0 (95% CI 3.3-4.7) among women who did not use pharmacotherapy, and 6.4 (95% CI 4.9-7.9) among women using methadone.
conclusionBuprenorphine use among Medicaid-enrolled pregnant women with opioid use disorder increased significantly over time, with a small concurrent decline in methadone use. Behavioral health counseling use was low, but highest among women using methadone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.